Category - pharmaceuticals

Antitrust Bayh-Dole Act Books Business Capitol Hill China Congress drug pricing Government House of Representatives independent inventor independent inventors innovation intellectual property International IP News IPWatchdog Articles Legislation patent Patents pharmaceuticals Senate technology Technology & Innovation

IP and Innovation on Capitol Hill: Week of March 4

This week on Capitol Hill and the Washington D.C. space, the Supreme Courtroom grants the petition in Iancu v. NantKwest; the U.S. Home of Representatives will...

#breakthepatent Access AIDS and Knowledge Bayh-Dole Act bio Books Business Centers for Disease Control and Prevention drug pricing Food and Drug Administration Generics Gilead Sciences Government HIV Initiative for Medicines IP News IPWatchdog Articles march-in rights National Institutes of Health orange book Patents pharmaceuticals PhRMA PrEP Technology & Innovation Truvada

Examining the Truvada #BreakThePatent Debate: Gilead Responds

We consider that one of many biggest limitations to Truvada for PrEP entry in the present day is restricted consciousness of Truvada for PrEP’s position in HIV...

biotech Books Guest Contributor Guest Contributors inter partes inter partes review IP News IPR IPR institution decisions IPWatchdog Articles orange book patent Patent Trial and Appeal Board Patents pharmaceuticals post grant procedures PTAB USPTO

More Orange Book Patents Are Surviving the ‘Death Squad’

“[I]t seems that the pendulum is swinging again in favor of Orange Ebook patent house owners. The variety of petitions difficult these patents has slowed...

Abbreviated New Drug Application ANDA Books CAFC Courts double patenting Federal Circuit Federal Circuit Review Gilenya Guest Contributors Hatch-Waxman Act IP News IPWatchdog Articles Judge Kimberly Moore Judge Ray Chen Judge Todd Hughes Novartis Novartis AG v. Ezra Ventures LLC obviousness type double patenting patent Patent Litigation Patents pharmaceutical patent law pharmaceuticals

Federal Circuit Upholds Patent Term Extension for Novartis Drug

The USA Courtroom of Appeals for the Federal Circuit lately affirmed a district courtroom determination discovering the ‘229 patent legitimate, unexpired...